Forget Crispr Therapeutics: This Gene-Editing Pick Attracts
The gene-editing field is maturing from hype to real profits. This article outlines why a broader set of players coul...
Using credit card points for travel deals can significantly reduce your expenses. Discover how to leverage your points for savings.
19,634 articlesThe gene-editing field is maturing from hype to real profits. This article outlines why a broader set of players coul...
Investing in high-growth EV names can be tempting when share prices dip. This guide helps you evaluate should rivian ...
Palantir’s AI-enabled analytics engine has fueled growth, but the stock faces multiple headwinds. This article lays o...
Venture funding in the U.S. hit a record in the first half of 2026, led by AI mega-deals, while exits skew toward Spa...
Netflix faces a crossroads: expand by merging with major studios or double down on core strengths. This piece argues ...
Investing in tomorrow’s energy tech can feel risky. This article outlines how a compact, early-stage stock could grow...
Fastly stock already doubled this year, leaving many investors wondering if the rally can continue. This guide breaks...
A discreet fund quietly builds a Mattel stake, signaling conviction or a calculated thesis. This article breaks down ...
Get a clear, real-world view of Ligand (LGND) 2026 earnings. This guide breaks down revenue sources, milestones, and ...
iQIYI faces a brutal 2026, but a new strategy focused on IP monetization and international growth could unlock sizabl...
As investors parse Nano-X Imaging's Q4 2025 results, this guide breaks down the numbers, the business model, and what...
A civil suit over a $100 million claim has escalated into a courtroom confrontation between Galaxy Digital founder Mi...